Activated Charcoal Aloe Aluminum Oxide Bryonia Alb
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- Activated Charcoal Aloe Aluminum Oxide Bryonia Alb
- Multi-component Botanical/Homeopathic Mixture: Insufficient Data, Unable to Complete Drug Repurposing Assessment
Multi-component Botanical/Homeopathic Mixture: Insufficient Data, Unable to Complete Drug Repurposing Assessment
One-sentence Summary
This candidate drug is a multi-component mixture containing 17 ingredients (activated charcoal, aloe, aluminum oxide, bryonia alba root, etc.), with no approved market authorization record in the United States and no DrugBank ID. The TxGNN model did not generate any novel indication predictions. Safety, mechanism of action, and clinical evidence data are currently insufficient; it is recommended to supplement basic drug information before proceeding with assessment.
Quick Overview
| Item | Content |
|---|---|
| Approved Indications | No approved indication record |
| Predicted Novel Indications | None (TxGNN generated no predictions) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (model unable to predict; no actual research available) |
| U.S. Market Status | ✗ Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is Prediction Inference Not Possible?
This candidate drug is a multi-component mixture containing:
Activated Charcoal, Aloe, Aluminum Oxide, Bryonia Alba Root, Chelidonium Majus, Collinsonia, Frangula Alnus Bark, Lycopodium Clavatum Spore, Potassium Carbonate, Rhubarb, Silybum Marianum Seed, Skatole, Sodium Carbonate, Strychnos Nux-Vomica Seed, Sus Scrofa Pancreas Extract, Taraxacum Officinale, Thiamine
The TxGNN knowledge graph method relies on mapping a single DrugBank ID to graph nodes. As this multi-component formulation is not registered in DrugBank, the system cannot identify any mappable nodes, and therefore no disease prediction results were generated.
From the ingredient composition, most components have traditional digestive system or hepatobiliary support uses (rhubarb and frangula alnus bark as laxatives; silybum marianum for hepatic support; taraxacum officinale as a digestive promoter; Sus Scrofa pancreas extract containing digestive enzymes), while some ingredients are homeopathic in nature (bryonia alba, strychnos nux-vomica, lycopodium clavatum). The overall character is oriented toward digestive support/hepatic protection formulations, but currently lacks mechanistic data to support any inference.
Clinical Trial Evidence
Currently, no related clinical trials are registered.
Literature Evidence
Currently, no related literature data are available.
U.S. Market Information
This product has no NDA approval record in the United States and its market status is Not marketed.
Safety Considerations
Please refer to individual package inserts for each ingredient for warnings and contraindications.
Special attention: Strychnos Nux-Vomica Seed contains strychnine, which has neurotoxicity and can be lethal at high doses. Before use, confirm the safe dosage range and homeopathic dilution ratio.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model was unable to generate any predictions because it could not identify DrugBank nodes in the multi-component formulation. Combined with the lack of U.S. approval record and absence of safety data, there is currently insufficient evidence to support proceeding with the assessment process.
To advance this candidate further, the following data must be supplemented:
- Clarify product classification: Determine whether this formulation is classified as a chemical drug, botanical drug, homeopathic preparation, or dietary supplement to establish the appropriate regulatory pathway
- Select key ingredient(s): From the 17 components, identify 1–3 main active ingredients with DrugBank IDs and resubmit to TxGNN for prediction
- Query DrugBank: For ingredients with DrugBank registration such as Silybum Marianum (silymarin), Frangula Alnus (frangulins), and Taraxacum Officinale, obtain mechanism of action data
- Safety data: Particularly confirm the safe dosage limit and toxicity risk for Strychnos Nux-Vomica Seed
- Define indications: If positioned for digestive/hepatic indications, at least Phase 2 clinical trial data is required to achieve L2 or higher evidence level
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.